@article{HolzmannLittigFrankSchmadereretal.2022,
  author    = {Holzmann-Littig, Christopher and Frank, Tamara and Schmaderer, Christoph and Braunisch, Matthias C. and Renders, Lutz and Kranke, Peter and Popp, Maria and Seeber, Christian and Fichtner, Falk and Littig, Bianca and Carbajo-Lozoya, Javier and Meerpohl, Joerg J. and Haller, Bernhard and Allwang, Christine},
  title     = {COVID-19 Vaccines: Fear of side effects among German health care workers},
  series = {Vaccines},
  volume    = {10},
  journal   = {Vaccines},
  number    = {5},
  issn      = {2076-393X},
  doi       = {10.3390/vaccines10050689},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270561},
  year      = {2022},
  abstract  = {(1) Background: Health care workers (HCWs) play a key role in increasing anti-COVID vaccination rates. Fear of potential side effects is one of the main reasons for vaccine hesitancy. We investigated which side effects are of concern to HCWs and how these are associated with vaccine hesitancy. (2) Methods: Data were collected in an online survey in February 2021 among HCWs from across Germany with 4500 included participants. Free-text comments on previously experienced vaccination side effects, and fear of short- and long-term side effects of the COVID-19 vaccination were categorized and analyzed. (3) Results: Most feared short-term side effects were vaccination reactions, allergic reactions, and limitations in daily life. Most feared long-term side effects were (auto-) immune reactions, neurological side effects, and currently unknown long-term consequences. Concerns about serious vaccination side effects were associated with vaccination refusal. There was a clear association between refusal of COVID-19 vaccination in one's personal environment and fear of side effects. (4) Conclusions: Transparent information about vaccine side effects is needed, especially for HCW. Especially when the participants' acquaintances advised against vaccination, they were significantly more likely to fear side effects. Thus, further education of HCW is necessary to achieve good information transfer in clusters as well.},
  language  = {en}
}
@article{KunathKrauseWullichetal.2013,
  author    = {Kunath, Frank and Krause, Steffen F. and Wullich, Bernd and Goebell, Peter J. and Engehausen, Dirk G. and Burger, Maximilian and Meerpohl, Joerg J. and Keck, Bastian},
  title     = {Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov},
  series = {BMC Urology},
  volume    = {13},
  journal   = {BMC Urology},
  number    = {56},
  doi       = {10.1186/1471-2490-13-56},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122133},
  year      = {2013},
  abstract  = {Background: Uro-oncological neoplasms have both a high incidence and mortality rate and are therefore a major public health problem. The aim of this study was to evaluate research activity in uro-oncology over the last decade. Methods: We searched MEDLINE and ClinicalTrials.gov systematically for studies on prostatic, urinary bladder, kidney, and testicular neoplasms. The increase in newly published reports per year was analyzed using linear regression. The results are presented with 95\% confidence intervals, and a p value <0.05 was considered statistically significant. Results: The number of new publications per year increased significantly for prostatic, kidney and urinary bladder neoplasms (all <0.0001). We identified 1,885 randomized controlled trials (RCTs); also for RCTs, the number of newly published reports increased significantly for prostatic (p = 0.001) and kidney cancer (p = 0.005), but not for bladder (p = 0.09) or testicular (p = 0.44) neoplasms. We identified 3,114 registered uro-oncological studies in ClinicalTrials.gov. However, 85\% of these studies are focusing on prostatic (45\%) and kidney neoplasms (40\%), whereas only 11\% were registered for bladder cancers. Conclusions: While the number of publications on uro-oncologic research rises yearly for prostatic and kidney neoplasms, urothelial carcinomas of the bladder seem to be neglected despite their important clinical role. Clinical research on neoplasms of the urothelial bladder must be explicitly addressed and supported.},
  language  = {en}
}